Percy Genyk
Cardiovascular Disease · Flemington, NJNPI 1033575535
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,770 of the $2,169 with a category attached, or 81.6%. It is spread thinly across 21 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $943, more than ten times the $67 reported in 2022. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 81 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$491
- Abbott$301
- Medtronic$281
- Novartis$242
- Pfizer$190
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$117
- plus $547 from 15 others
What the payments were for
- Travel & lodging$39918%
- Food & beverage$1,77082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 3 | $491 |
| Abbott | 2 | $301 |
| Medtronic | 10 | $281 |
| Novartis | 15 | $242 |
| Pfizer | 18 | $190 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $117 |
| Novo Nordisk | 1 | $105 |
| Cleerly, Inc. | 4 | $84 |
| Amgen | 4 | $66 |
| Abiomed | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Bayer | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $14 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,169 in reported general payments places this provider in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Flemington
- Austin KutscherFlemington$117K
- Andrey EspinozaFlemington$59K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.